Tag: clearside biomedical

January 21, 2019

Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE

Clearside Biomedical (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye...
December 20, 2018

Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis

Clearside Biomedical (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye...
March 14, 2018

Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update

Clearside Biomedical (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results...
March 8, 2018

Clearside Announces Pricing of Public Offering of Common Stock

Clearside Biomedical (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the pricing...
March 5, 2018

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA

Clearside Biomedical (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced positive topline results...
April 20, 2017

Clearside Biomedical Completes Enrollment for Phase 1/2 Trial

Clearside Biomedical has finalized the enrollment for its clinical trial of CLS-TA in treating diabetic macular edema.
February 16, 2017

Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment...